BidaskClub Lowers Antares Pharma (ATRS) to Hold

Share on StockTwits

BidaskClub cut shares of Antares Pharma (NASDAQ:ATRS) from a buy rating to a hold rating in a research report released on Tuesday morning.

ATRS has been the subject of several other reports. TheStreet raised shares of Antares Pharma from a d rating to a c rating in a research note on Friday, March 1st. Cowen assumed coverage on shares of Antares Pharma in a research note on Monday, February 25th. They set an outperform rating and a $1.99 price objective for the company. Finally, Raymond James upped their price objective on shares of Antares Pharma from $5.25 to $5.65 and gave the company a strong-buy rating in a research note on Monday, March 4th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Antares Pharma presently has a consensus rating of Buy and a consensus price target of $4.83.

Shares of NASDAQ:ATRS opened at $3.31 on Tuesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.20 and a current ratio of 2.62. Antares Pharma has a 12 month low of $1.99 and a 12 month high of $3.96.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Thursday, February 28th. The specialty pharmaceutical company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.07. Antares Pharma had a negative net margin of 10.25% and a negative return on equity of 22.42%.

In related news, Director Jacques Gonella sold 200,000 shares of the stock in a transaction dated Tuesday, February 26th. The shares were sold at an average price of $3.65, for a total value of $730,000.00. Following the completion of the transaction, the director now directly owns 9,385,848 shares of the company’s stock, valued at $34,258,345.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 12.20% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in ATRS. Sargent Investment Group LLC bought a new position in Antares Pharma in the fourth quarter worth about $8,422,000. Millennium Management LLC raised its stake in Antares Pharma by 118.2% in the fourth quarter. Millennium Management LLC now owns 1,507,964 shares of the specialty pharmaceutical company’s stock worth $4,102,000 after buying an additional 816,798 shares in the last quarter. Fosun International Ltd bought a new position in Antares Pharma in the fourth quarter worth about $1,414,000. Essex Investment Management Co. LLC bought a new position in Antares Pharma in the fourth quarter worth about $1,377,000. Finally, JPMorgan Chase & Co. raised its stake in Antares Pharma by 112.2% in the third quarter. JPMorgan Chase & Co. now owns 941,117 shares of the specialty pharmaceutical company’s stock worth $3,162,000 after buying an additional 497,523 shares in the last quarter. 42.20% of the stock is owned by institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Featured Story: What is a trade deficit?

Analyst Recommendations for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Investors Buy Large Volume of Cerner Put Options
Investors Buy Large Volume of Cerner Put Options
Traders Purchase Large Volume of Call Options on American Tower
Traders Purchase Large Volume of Call Options on American Tower
PriceSmart  Trading Up 7.3% Following Better-Than-Expected Earnings
PriceSmart Trading Up 7.3% Following Better-Than-Expected Earnings
KLX Energy Services  & Its Competitors Head-To-Head Review
KLX Energy Services & Its Competitors Head-To-Head Review
$818.32 Million in Sales Expected for First Republic Bank  This Quarter
$818.32 Million in Sales Expected for First Republic Bank This Quarter
$140.57 Million in Sales Expected for Lindsay Co.  This Quarter
$140.57 Million in Sales Expected for Lindsay Co. This Quarter


© 2006-2019 Ticker Report